Oscar Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oscar Health (OSCR).

Price Target Range — 13 Quarters

Analyst Consensus — 8 Analysts

3Buy

4Hold

1Sell

Consensus RatingNeutral# Analysts8Avg. Consensus PT$29Upside to Avg. PT-10.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$26→$36
Sep 18, 2026	Raymond James	John Ransom	PT Raise	Outperform	$34→$42
Sep 17, 2026	B of A Securities	Adam Ron	PT Raise	Underperform	$28→$30
Sep 17, 2026	Stephens & Co.	Raj Kumar	Maintained	Equal-Weight	$34
Sep 17, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$39→$49
Sep 17, 2026	Baird	Michael Ha	PT Raise	Neutral	$27→$33
Aug 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Equal-Weight	$20→$27
Aug 7, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$20→$26
Aug 7, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$35→$39
Jun 10, 2026	Barclays	Andrew Mok	Upgrade	Equal-Weight→Overweight	$30→$35
May 26, 2026	Barclays	Andrew Mok	PT Raise	Equal-Weight	$21→$30
May 7, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$15→$20
May 7, 2026	Barclays	Andrew Mok	PT Raise	Equal-Weight	$18→$21
May 7, 2026	Baird	Michael Ha	PT Raise	Neutral	$15→$19
May 6, 2026	Wolfe Research	Justin Lake	Initiate	Peer Perform	—
Apr 20, 2026	Jefferies	David Windley	Upgrade	Underperform→Hold	$10→$16
Jan 9, 2026	UBS	Jonathan Yong	Upgrade	Sell→Neutral	$12→$17
Jan 5, 2026	Barclays	Andrew Mok	Upgrade	Underweight→Equal-Weight	$13→$18
Dec 11, 2025	Stephens & Co.	Dean Sublett	Initiate	Equal-Weight	$17
Nov 26, 2025	Piper Sandler	Jessica Tassan	Upgrade	Neutral→Overweight	$13→$25

Analyst Ratings News

PRO
UBS Maintains Neutral on Oscar Health, Raises Price Target to $36

UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $26 to $36.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on Oscar Health, Raises Price Target to $42

Raymond James analyst John Ransom maintains Oscar Health (NYSE:OSCR) with a Outperform and raises the price target from $34 to $42.

Benzinga Newsdesk

PRO
B of A Securities Maintains Underperform on Oscar Health, Raises Price Target to $30

B of A Securities analyst Adam Ron maintains Oscar Health (NYSE:OSCR) with a Underperform and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
Stephens & Co. Reiterates Equal-Weight on Oscar Health, Maintains $34 Price Target

Stephens & Co. analyst Raj Kumar reiterates Oscar Health (NYSE:OSCR) with a Equal-Weight and maintains $34 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Oscar Health, Raises Price Target to $49

Barclays analyst Andrew Mok maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $39 to $49.

Benzinga Newsdesk

PRO
Baird Maintains Neutral on Oscar Health, Raises Price Target to $33

Baird analyst Michael Ha maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $27 to $33.

Benzinga Newsdesk

Oscar Health Inc

Oscar Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Oscar Health, Raises Price Target to $36

PRO
Raymond James Maintains Outperform on Oscar Health, Raises Price Target to $42

PRO
B of A Securities Maintains Underperform on Oscar Health, Raises Price Target to $30

PRO
Stephens & Co. Reiterates Equal-Weight on Oscar Health, Maintains $34 Price Target

PRO
Barclays Maintains Overweight on Oscar Health, Raises Price Target to $49

PRO
Baird Maintains Neutral on Oscar Health, Raises Price Target to $33

People Also Watch

People Also Watch

Oscar Health Inc

Oscar Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Oscar Health, Raises Price Target to $36

PRORaymond James Maintains Outperform on Oscar Health, Raises Price Target to $42

PROB of A Securities Maintains Underperform on Oscar Health, Raises Price Target to $30

PROStephens & Co. Reiterates Equal-Weight on Oscar Health, Maintains $34 Price Target

PROBarclays Maintains Overweight on Oscar Health, Raises Price Target to $49

PROBaird Maintains Neutral on Oscar Health, Raises Price Target to $33

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Oscar Health, Raises Price Target to $36

PRO
Raymond James Maintains Outperform on Oscar Health, Raises Price Target to $42

PRO
B of A Securities Maintains Underperform on Oscar Health, Raises Price Target to $30

PRO
Stephens & Co. Reiterates Equal-Weight on Oscar Health, Maintains $34 Price Target

PRO
Barclays Maintains Overweight on Oscar Health, Raises Price Target to $49

PRO
Baird Maintains Neutral on Oscar Health, Raises Price Target to $33